Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activate and resist: L576P-KIT in GIST.

Molecular cancer therapeutics - 1 Sept 2009

Conca Elena, Negri Tiziana, Gronchi Alessandro, Fumagalli Elena, Tamborini Elena, Pavan Giovanni Maria, Fermeglia Maurizio, Pierotti Marco A, Pricl Sabrina, Pilotti Silvana

Abstract excerpt

L576P is a rare KIT mutation often reported in cancers other than gastrointestinal stromal tumors (GIST). In GISTs, it correlates with features linked to an aggressive phenotype, eventually resulting in secondary mutations. In vitro findings point out that L576P/KIT is constitutively activated, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gastrointestinal Stromal Tumors
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Receptor, Platelet-Derived Growth Factor alpha

Source

Identifiers

PMID: 19723893
DOI: 10.1158/1535-7163.MCT-09-0662

Genes

KIT
BRAF
NRAS
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19723893-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activate and resist: L576P-KIT in GIST.PMID 19723893Read ↗

p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?Semantic proximity Read ↗

Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.Semantic proximity Read ↗

Targeted therapies in gastrointestinal stromal tumors.Semantic proximity Read ↗

KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Semantic proximity Read ↗

A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.Semantic proximity Read ↗

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read ↗

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GISTSemantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

The GIST paradigm: lessons for other kinase‐driven cancersSemantic proximity Read ↗

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.Semantic proximity Read ↗

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.Semantic proximity Read ↗

Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.